Physician profile
James D Ellner
NPI 1720138696
$10,052.33
in general payments reported to CMS, 2019-2025
35 companies · $2,411 in 2025
The $2,411 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $1,146 · 2021: $1,637 · 2022: $1,170 · 2023: $844 · 2024: $813 · 2025: $2,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,054 · Education: $14.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.05 |
| Education | $14.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $4,779.27 | 2019-2024 | Senza |
| Abbott Laboratories | $1,049.23 | 2019-2025 | Proclaim |
| Medtronic, INC. | $983.71 | 2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Globus Medical, INC. | $882.16 | 2025 | Senza, Omnia, Vyrsa V1 |
| Medtronic USA, INC. | $586.99 | 2019-2020 | |
| Boston Scientific Corporation | $351.14 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.00 | 2019-2025 | Relistor |
| Almatica Pharma LLC | $168.56 | 2021-2023 | Gralise |
| Horizon Therapeutics Plc | $88.42 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $69.82 | 2021-2022 | |
| Biotronik Nro, INC. | $67.07 | 2024-2025 | Prospera |
| Pfizer INC. | $59.28 | 2019-2021 | |
| Amgen INC. | $55.38 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $54.38 | 2021 | |
| Vertos Medical, INC. | $40.37 | 2024 | Mild Device Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $35.28 | 2019-2024 | |
| Spr Therapeutics, INC | $33.59 | 2023-2025 | Sprint Pns System |
| Redhill Biopharma INC. | $32.87 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $31.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.18 | 2019 | |
| Protega Pharmaceutials INC | $29.90 | 2023 | Roxybond |
| Kowa Pharmaceuticals America, INC. | $28.80 | 2022 | |
| Assertio Therapeutics, INC. | $27.39 | 2019 | |
| Averitas Pharma INC. | $26.31 | 2025 | Qutenza |
| Virtus Pharmaceuticals LLC | $24.77 | 2021 | |
| Spinal Simplicity, LLC | $24.43 | 2025 | Ha Minuteman G3-R |
| Grt US Holding, INC. | $22.77 | 2021 | |
| Atland Pharmaceuticals, LLC | $22.08 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Saluda Medical Americas, INC. | $21.49 | 2023 | Evoke Scs |
| Hikma Pharmaceuticals USA | $21.46 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.12 | 2025 | Horizant |
| Pacira Pharmaceuticals Incorporated | $17.98 | 2025 | Iovera, Zilretta |
| Valinor Pharma, LLC | $17.14 | 2025 | Movantik |
| Nalu Medical, INC. | $14.31 | 2022 | |
| Daiichi Sankyo INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ellner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.